Anagrelide

CLINICAL USE

Platelet-reducing agent

DOSE IN NORMAL RENAL FUNCTION

1–10 mg daily in divided doses; maximum
single dose 2.5 mg; normal range 1–3 mg
daily

PHARMACOKINETICS

Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :
292.5 (as
hydrochloride)

%Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :
No data

%Excreted unchanged in urine &nbsp &nbsp :
<1

Volume of distribution (L/kg) &nbsp &nbsp &nbsp :
12

half-life – normal/ESRD (hrs)&nbsp &nbsp &nbsp :
1.3

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

30–50 Dose as in normal renal function
10–30 Dose as in normal renal function,
but use with caution and keep to
lowest dose possible

<10 &nbsp &nbsp &nbsp &nbsp &nbsp : Dose as in normal renal function, but use with caution and keep to lowest dose possible

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:
Unknown dialysability. Dose as in
GFR <10 mL/min

HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :
Unknown dialysability. Dose as in
GFR <10 mL/min

HDF/high flux &nbsp :
Unknown dialysability. Dose as in
GFR <10 mL/min

CAV/VVHD &nbsp &nbsp &nbsp:
Unknown dialysability. Dose as in
GFR=10–30 mL/min

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugs

Cilostazol: avoid concomitant use

Phosphodiesterase inhibitors: avoid

concomitant use with milrinone and
enoximone

spirin: potential risks and benefits must

first be assessed, additive antiplatelet effect

Grapefruit juice: may reduce clearance of

anagrelide

ADMINISTRATION

Reconstition

–

Route

Oral

Rate of Administration

–

Comments

–

OTHER INFORMATION

May cause fluid retention, tachycardia and

various cardiac complications

Rarely can increase creatinine levels

High doses can cause a drop in blood

pressure

Tags: post-by-auto-php